Pentazocine 25mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Pentazocine hydrochloride

Available from:

A A H Pharmaceuticals Ltd

ATC code:

N02AD01

INN (International Name):

Pentazocine hydrochloride

Dosage:

25mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

Schedule 3 (CD No Register Exempt Safe Custody)

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 04070200; GTIN: 5025903003250

Patient Information leaflet

130x210 Leaflet Reel Fed Profile (BST)
Dimensions:
Component:
Date Sent:
Technologist: TECHNICALLY APPROVED
Pharmacode:
JDE No.:
Pentazocine, Tablets, 25 mg,
28s - UK
130x210 (Reel Fed)
50985590
Leaflet for Bottles
7184
RH
16-12-19
* Please note that ONLY Artwork Studio is permitted to make changes to
the above artwork.
No changes are permitted by any 3rd party other than added notes and
mark ups for required changes.
approved for print/date
PROOF ROUND
Technical
Approval
NON PRINTING COLOURS
COLOURS
DATE SENT:
DATE RECEIVED:
Item number:
ORIGINATOR:
ORIGINATION DATE:
REVISION DATE:
REVISED BY:
DIMENSIONS:
MIN BODY TEXT SIZE:
SUPPLIER:
1.
2.
3.
4.
5.
6.
1.
2.
3.
GTIN 13
(Belgium & Slovenia):
[e-mail]
PENTAZOCINE HYDROCHLORIDE 25MG 28 TABLETS PIL - UK
Black
Profile
BBBA7195
S.Anson
03.01.20
07.01.20
S.Anson
130 x 210
7pt
Accord Barnstaple
n/a
n/a
2
Version 6
12.12.2019
German GTIN 14
(incorporating PZN):
Cartons and label leaflets only
(labels only when specified)
PENTAZOCINE 25MG TABLETS
(Pentazocine Hydrochloride)
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
THIS MEDICINE CONTAINS PENTAZOCINE HYDROCHLORIDE WHICH IS
AN OPIOID, WHICH CAN CAUSE ADDICTION. YOU CAN GET WITHDRAWAL
SYMPTOMS IF YOU STOP TAKING IT SUDDENLY.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on
to others. It may harm them, even if their signs of illness are the
same as yours.
• If you get any side effects talk to your doctor or pharmacist.
This
includes any possible side effects not listed in this leaflet. See
section 4.
WHAT IS IN THIS LEAFLET:
1
WHAT PENTAZOCINE TABLETS ARE AND WHAT THEY ARE
USED FOR
2
WHAT YOU NEED TO KNOW BEFORE YOU TAKE PENTAZOCINE
TABLETS
3
HOW TO TAKE PENTAZOCINE TABLETS
4
POSSIBLE SIDE EFFECTS
5
HOW TO STORE PENTAZOCINE T

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
PENTAZOCINE TABLETS BP 25mg
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 25mg Pentazocine Hydrochloride BP.
Excipient(s) with known effect:
Each tablet contains
200.00mg
lactose
monohydrate
For the full list of excipients, see section 6.1
3
PHARMACEUTICAL FORM
White uncoated tablets.
White, circular, biconvex uncoated tablets impressed “C” and the
identifying
letters “PZ” on one face.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
For the relief of moderate to severe pain.
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
Prior to starting treatment with opioids, a discussion should be held
with
patients to put in place a strategy for ending treatment with
pentazocine
hydrochloride in order to minimise the risk of addiction and drug
withdrawal
syndrome (see section 4.4).
Posology
The dosage is usually tailored to the individual patient and to the
severity of
the pain.
_ _
_Adults_
The usual initial dosage is two 25 mg tablets (50mg) every four hours
after
meals followed by 25mg to 100mg of pentozocine every three to four
hours.
_ _
_Elderly _
Since impaired renal or hepatic function is often associated with
ageing,
elderly patients may require smaller doses of pentazocine.
_ _
_Paediatric population _
_6-12 years:_ One 25mg tablet every three to four hours as necessary.
Pentazocine tablets are not recommended for children under 6 years of
age. No data are available.
Method of administration
For oral use.
4.3
CONTRAINDICATIONS
- Hypersensitivity to the active substance or to any of the excipients
listed in
section 6.1.
- Pentazocine should not be administered to patients with established
respiratory depression, especially in the presence of cyanosis and
excessive
bronchial secretion
- Acute alcoholism
- Acute bronchial asthma
- Heart failure secondary to chronic lung disease
- Porphyria
- Raised intracranial pressure, head injuries or pathological brain
conditions
where clouding of the sensorium is undesirable.
4.4.
SPECIA